An arbitration tribunal in Singapore is now said to have asked the Singh brothers, Malvinder and Shivinder, and certain group firms to cough up damages of around INR25.62bn ($385m) in a case involving damages over Daiichi Sankyo Co. Ltd.‘s past acquisition of Ranbaxy Laboratories Ltd.
Golden Week For Daiichi: Damages Due From Ranbaxy Brothers
In what seems like some consolation for Daiichi Sankyo after its disastrous acquisition of Ranbaxy Laboratories and subsequent divestment of the Indian company, arbitration proceedings in Singapore against the Singh brothers of Ranbaxy have gone the Japanese firm's way.
More from Focus On Asia
• By
Plus deals involving Elix/PRISM, Rege/Syros, Kaken/KalVista, Dr. Reddy’s/Aurigene/Edity, Nissan Chemical/Sanwa, Lupin/Renascience, Shionogi/Link Medicine, Abbisko/Merck & Co., Ono/Reborna and Apollomics/LaunXp.
• By
Japanese incubator Ciconia has just started verifying its first drug candidate with a vision of building domestic startups with globally competitive assets.
• By
While Henlius Biotech’s PD-L1-targeting antibody-drug conjugate HLX43 is struggling to catch up with Pfizer’s PF-08046054, the global frontrunner in the space, a key differentiation of the China-originated asset could lie in PD-L1-negative patients.
• By
Although pharmaceuticals are exempt from the US reciprocal tariff policy, for now, the escalating global trade war is already posing practical on-the-ground problems for some companies, Scrip hears.
More from Scrip
• By
The agency loosened requirements for echocardiograms and removed contraindications for a number of commonly used drugs.
• By
The IL-4/IL-13 inhibitor has been approved in the US as the first targeted therapy in over a decade for chronic itching.
• By
Japanese incubator Ciconia has just started verifying its first drug candidate with a vision of building domestic startups with globally competitive assets.